Skip to main content

Show 30 results Show all

Subcutaneous DMPA key facts: Answering questions and dispelling common myths about a new type of injectable contraception

This brief offers concise, evidence-based information to help answer common questions and dispel myths about injectable contraception. Myths are not stated directly because repeating a myth may reinforce it in people’s minds.

Institutional Author(s): PATH
Publication date: October, 2019

PowerPoint template: Expanding options and access with subcutaneous DMPA, a new type of injectable contraception

This customizable slide deck provides a brief description of DMPA-SC and its benefits; an overview of evidence on how the product expands access through multiple delivery channels; and illustrative policy and advocacy gaps and recommendations for country decision-makers.

Institutional Author(s): PATH
Publication date: October, 2019

Association Between the Quality of Contraceptive Counseling and Method Continuation: Findings From a Prospective Cohort Study in Social Franchise Clinics in Pakistan and Uganda

Quality of family planning counseling is likely associated with whether or not women continue to use the same contraceptive method over time. The Method Information Index (MII) is a widely available measure of contraceptive counseling quality but little is known about its association with rates of method continuation. Using data from a prospective cohort study of 1,998 social franchise clients in Pakistan and Uganda, we investigated the relationship between reported baseline MII and the risk of method continuation over 12 months using survival analysis and Cox proportional hazard models. Higher scores on the 3-question Method Information Index (MII)—measuring client-reported receipt of contraceptive information—was associated with continued use of family planning over 12 months. We recommend incorporating use of the MII in routine assessments of family planning service quality.

Global Health: Science and Practice. March 2019, 7(1):87-102. https://doi.org/10.9745/GHSP-D-18-00407

 

Institutional Author(s): Metrics for Management, Population Council, Wilfrid Laurier University, Population Services International (PSI), MSI Reproductive Choices, Makerere University
Individual Author(s): Nirali M. Chakraborty, Karen Chang, Benjamin Bellows, Karen A. Grépin, Waqas Hameed, Amanda Kalamar, Xaher Gul, Lynn Atuyambe, Dominic Montagu
Publication date: March, 2019

Journal Article Association Between the Quality of Contraceptive Counseling and Method Continuation: Findings From a Prospective Cohort Study in Social Franchise Clinics in Pakistan and Uganda

Common terms for DMPA injectable contraception

This brief helps you understand the terms surrounding DMPA injectables to inform your messaging and communication.

Institutional Author(s): PATH
Publication date: 2017

Operational assessments of Sayana® Press provision in Senegal and Uganda

This study aimed to evaluate DMPA-SC (Sayana Press) management and administration in low-resource settings, focusing on how the delivery logistics, administration time, storage and waste-management requirements compare to the traditional intramuscular DMPA injectable (DMPA-IM).

Cover J, Blanton E, Ndiaye D, Walugembe F, Lamontagne DS. Operational assessments of Sayana® Press provision in Senegal and Uganda. Contraception. 2014 May;89(5):374-8. https://doi.org/10.1016/j.contraception.2014.01.005. Epub 2014 Jan 18. PMID: 24565737.

Institutional Author(s): PATH
Individual Author(s): Jane Cover, Elizabeth Blanton, Dieynaba Ndiaye, Fiona Walugembe, D Scott Lamontagne
Publication date: January, 2014

Journal Article Operational assessments of Sayana® Press provision in Senegal and Uganda

Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm

This study evaluated the pharmacokinetic profile of medroxyprogesterone acetate (MPA) following injection of Depo-SubQ Provera 104 (DMPA-SC) in the upper arm, a preferred injection site in developing countries. Injection of Depo-SubQ Provera 104™ in the upper arm provided sufficient MPA levels for contraceptive protection for 3 months (13 weeks). The uptake and metabolism of MPA when injected in the upper arm may be different from the abdomen and thigh.

 

Institutional Author(s): FHI 360
Individual Author(s): Vera Halpern, Stephanie L Combes, Laneta J Dorflinger, Debra H Weiner, David F Archer
Publication date: July, 2013

Journal Article Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm

Acceptability of depo-subQ in Uniject

FHI 360’s PROGRESS project worked with ministries of health and local partners in Senegal and Uganda to conduct an acceptability study of the subcutaneous delivery of injectable contraceptives with the Uniject™ device (DMPA-SC, Sayana® Press). The study assessed acceptability among family planning clients and providers, including community health workers, and offered recommendations for the introduction of this method.

Institutional Author(s): FHI 360
Publication date: June, 2013

Operational Assessment: Administration and Management of Sayana® Press in Clinics and Communities in Uganda

This operational assessment in Uganda examines the extent to which DMPA-SC (brand name Sayana® Press) facilitates the logistics of managing and administering injectable contraception and assesses whether providers in Uganda find benefits in this new presentation.

Institutional Author(s): PATH
Publication date: May, 2013

Brief Operational Assessment: Administration and Management of Sayana® Press in Clinics and Communities in Uganda

Logistics and Waste Management Benefits of depo-subQ in Uniject

This four-page brief describes results from three analyses conducted by PATH and John Snow Inc. (JSI) comparing the intramuscular version of depot medroxyprogesterone acetate (DMPA) injectable contraceptive compared with the new DMPA-SC formulation packaged in the Uniject injection system. The analyses focused on waste management implications and identified key quantitative and qualitative differences between the two products.

Institutional Author(s): PATH, JSI, Inc.
Publication date: February, 2011